

Scholar Rock to Present at Cowen's 42nd Annual Health Care Conference

February 25, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2022-- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in an Orphan Neuro and Neuromuscular panel discussion at Cowen's 42 nd Annual Health Care Conference on Monday, March 7, 2022 at 9:10 a.m. ET.

A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on the Company's website for approximately 30 days following the presentation.

About Scholar Rock

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock's approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.scholarRock.com or follow Scholar Rock on Twitter (www.scholarRock.com or follow Scholar Rock on Twitter (www.linkedin.com/company/scholar-rock/).

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

View source version on <u>businesswire.com</u>: https://www.businesswire.com/news/home/20220225005011/en/

Scholar Rock Contact:

Investors
Rushmie Nofsinger
Scholar Rock
rnofsinger@scholarrock.com
857-259-5573

Media

Ariane Lovell
Finn Partners
ariane.lovell@finnpartners.com
917-565-2204

Source: Scholar Rock